BioPharma's slowdown raises questions on 2026 organic growth target
23/07/26 -"Eurofins’ H1 results were in line with expectations on revenues but ahead of them on adjusted EBITDA. Organic growth improved sequentially with resilient growth in Life and good growth in ..."
Pages
49
Language
English
Published on
23/07/26
You may also be interested by these reports :
24/07/26
SGS saw organic growth accelerate in Q2 across NR, H&N and C&P, alongside resilient growth in Certification. However, growth in I&E was impacted by ...
23/07/26
Eurofins’ H1 results were in line with expectations on revenues but ahead of them on adjusted EBITDA. Organic growth improved sequentially with ...
22/07/26
Organic revenue growth accelerated in Q2 2026, driven by Operational and Enterprise segments, with growth returning in North America and Germany. ...
17/07/26
DKSH’s H1 ‘26 results were a mixed bag, with sales and EPS ahead of market expectations, but Core EBIT was below consensus due to Consumer Goods ...